CIK 0001789972
- Non-accelerated filer
- Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813879991
- Phone
- +1 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-08-04 | F2 Vision SCS 10% owner | Sale | −25,989 | $14.31 | $372K | 1,255,963 |
| 2022-08-03 | F2 Vision SCS 10% owner | Sale | −19,129 | $14.24 | $272K | 1,281,952 |
| 2022-08-02 | F2 Vision SCS 10% owner | Sale | −4,792 | $14.10 | $68K | 1,301,081 |
| 2022-05-16 | F2 Vision SCS 10% owner | Sale | −35,158 | $11.23 | $395K | 1,305,873 |
| 2022-05-13 | F2 Vision SCS 10% owner | Sale | −85,319 | $9.96 | $850K | 1,375,220 |
| 2022-05-13 | F2 Vision SCS 10% owner | Sale | −34,189 | $10.48 | $358K | 1,341,031 |
| 2022-05-12 | F2 Vision SCS 10% owner | Sale | −264,072 | $9.25 | $2.4M | 1,460,539 |
Page 1 of 1 · 7 trades